Starting Dose 0.3 mg In the phase 2 weight study, dosing started low at 0.3 mg weekly and was raised every 2 weeks to reduce nausea [1]
Lab testing may be recommended, but its not always required to begin treatment

Studies have shown that BPC-157 [8]: Modulates GABA receptor function Influences dopaminergic system activity Affects serotonergic pathways May help normalize neurotransmitter imbalances caused by various toxins These effects contribute to BPC-157's observed: Anxiolytic (anti-anxiety) properties in animal models Protection against dopaminergic neurotoxins Potential applications in alcohol withdrawal and drug-induced neurological damage Gut motility regulation Angiogenesis Promotion Beyond VEGF upregulation, BPC-157 promotes angiogenesis through multiple coordinated mechanisms [9]: Direct stimulation of endothelial cell proliferation Enhanced endothelial cell migration Improved capillary tube formation Blood vessel maturation and stabilization Collateral vessel development around blocked arteries This robust angiogenic effect helps explain why BPC-157 appears effective for tissues with naturally poor blood supply (tendons, ligaments, cartilage) and why it may support recovery from ischemic injuries

Kbe T, Witte AV, Schnelle A, et al
With a half-life of 6 to 8 days, this means retatrutide takes roughly 24 to 40 days to fully clear from your system after your last injection
These physician-supervised protocols are tailored to your individual wellness needs for meaningful, lasting results